Sanofi-Owkin Expand AI Collaboration With New Agentic AI Initiative

Owkin and Sanofi expand their AI partnership with a five-year deal to develop agentic systems aimed at accelerating drug research.

Arcus Biosciences Enters Clinical Trial Collaboration And Supply Agreement With Bristol Myers Squibb; Will Supply Casdatifan, Its Investigational Small-Molecule HIF-2a Inhibitor

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune

SystImmune And Bristol Myers Squibb Announce Sichuan Biokin Reports Results From Prespecified Interim Analyses Of Two Phase 3 Studies Evaluating Izalontamab Brengitecan

Interim analyses from PANKU-Breast02 (BL-B01D1-307) and PANKU-Esophagus01 (BL-B01D1-305) presented at ASCO® 2026SystImmune and Bristol Myers Squibb's potent dual-targeted EGFRxHER3 bispecific antibody-drug conjugate

Why Is Replimune Stock Gaining Monday?

Replimune Group (REPL) shares gain on key RP2 & RP1 oncology data presentations at ASCO. Read the clinical trial results.

Full Transcript: Bristol-Myers Squibb Q1 2026 Earnings Call

Bristol Myers Squibb Says FDA Accepts Snda For Camzyos As Potential Treatment For Adolescents With Symptomatic oHCM; PDUFA Date Set September 30

Camzyos has the potential to be the first pharmacological therapy for the treatment of oHCM in adolescents, addressing a high unmet need for this populationApplication based on positive results of Phase 3 SCOUT-HCM

Bristol Myers Squibb Announces European Commission Approval Of Opdivo In Combination With Doxorubicin, Vinblastine And Dacarbazine For The Treatment Of Adult And Adolescent Patients 12 Years

This approval marks a significant milestone, establishing the Opdivo plus AVD combination as the first immunotherapy-based regimen available in the European Union (EU) for newly diagnosed advanced cHL.1This new EC

Wall Street's Most Accurate Analysts Give Their Take On 3 Healthcare Stocks Delivering High-Dividend Yields

In turbulent markets, investors turn to dividend-yielding stocks. Here are analyst ratings for high-yielding energy stocks.

Bistol Myers Squibb Announces Results From Its Phase 3 SUCCESSOR-2 Trial Of CELMoD Mezigdomide In Combination With Carfilzomib And Dexamethasone In Patients With Relapsed Or Refractory Multip

Bristol Myers Squibb (NYSE:BMY) today announced positive late-breaking results from the Phase 3 SUCCESSOR-2 trial (NCT05552976) of CELMoD (cereblon E3 ligase modulation) mezigdomide in combination with carfilzomib and

Anthropic And OpenAI--Building Different Competitive Advantages

Bristol Myers deploys Claude enterprise AI to 30,000 workers as Anthropic stacks enterprise wins against a fast-moving OpenAI.